Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL
Дата публикации: 27-08-2026 00:00:00

Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors05.2127-08-2026
2Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma0509-07-2026
3Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma0502-07-2026
4Ultralow-Dose IL 10–Expressing CAR T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma014.6223-07-2026
5Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature review013.2320-08-2026
6Landmark NHS approval of cancer drugs offers new hope for children and adults with rare blood cancers011.7717-07-2026
7Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma013.2228-11-2023
8Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer08.6401-08-2026
9Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer014.2801-01-2025
10ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY02.327-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 2.16. Источник: escholarship.org.